Rise of Mucormycosis during the COVID-۱۹ Pandemic and the Challenges Faced
Publish place: Current Medical Mycology، Vol: 9، Issue: 1
Publish Year: 1402
نوع سند: مقاله ژورنالی
زبان: English
View: 89
This Paper With 12 Page And PDF Format Ready To Download
- Certificate
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
JR_CUMM-9-1_008
تاریخ نمایه سازی: 9 آذر 1402
Abstract:
Mucormycosis (previously called zygomycosis) is a diverse group of increasingly recognized and frequently fatal mycotic diseases caused by members of the class zygomycetes. Mucormycosis is around ۸۰ times more common in India, compared to other developed countries, with a frequency of ۰.۱۴ cases per ۱,۰۰۰ population. The most frequent causative agent of mucormycosis is the following genera from the Order Mucorales: Rhizopus, Mucor, Rhizomucor, Absidia, Apophysomyces, Cunninghamella, and Saksenaea. The major risk Mucormycosis (previously called zygomycosis) is a diverse group of increasingly recognized and frequently fatal mycotic diseases caused by members of the class zygomycetes. Mucormycosis is around ۸۰ times more common in India, compared to other developed countries, with a frequency of ۰.۱۴ cases per ۱,۰۰۰ population. The most frequent causative agent of mucormycosis is the following genera from the Order Mucorales: Rhizopus, Mucor, Rhizomucor, Absidia, Apophysomyces, Cunninghamella, and Saksenaea. The major risk factors for the development of mucormycosis are diabetic ketoacidosis, deferoxamine treatment, cancer, solid organ or bone marrow transplantations, prolonged steroid use, extreme malnutrition, and neutropenia. The common clinical forms of mucormycosis are rhino-orbital-cerebral, pulmonary, cutaneous, and gastrointestinal. During the second wave of COVID-۱۹, there was a rapid increase in mucormycosis with more severity than before. Amphotericin B is currently found to be an effective drug as it is found to have a broad spectrum activity and posaconazole is used as a salvage therapy. Newer triazole isavuconazole is also found effective against mucormycosis. This article aimed to review various studies on the laboratory diagnosis and treatment of mucormycosis.
Keywords:
Authors
Malavika Kottarathil
Department of Microbiology, Sri Ramachandra Institute of Higher Education and Research, Chennai, India
Thayanidhi Premamalini
Department of Microbiology, Sri Ramachandra Institute of Higher Education and Research, Chennai, India
Sathyamurthy P
Department of General Medicine, Sri Ramachandra Institute of Higher Education and Research, Chennai, India
Anupma Kindo
Department of Microbiology, Sri Ramachandra Institute of Higher Education and Research, Chennai, India
مراجع و منابع این Paper:
لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :